COVID-19 | FDA approves Moderna and J&J booster doses and combined use of vaccines

The US drug regulatory agency approved Wednesday the use of a vaccine against COVID-19 different for the booster dose than that originally used for immunization, according to a statement.

The Food and Drug Administration (FDA) also approved l, and Moderna’s for certain at-risk populations, including the elderly.

“The FDA has determined that the known and potential benefits of using a single different booster dose outweigh the known and potential risks of its use in eligible populations “the agency said in a statement.

Pfizer, Moderna, and Johnson & Johnson vaccines are licensed in the United States. Now I know, even if it is from a different laboratory than the vaccination I received initially.

Under the new decision, people who received two injections of Moderna initially and are 65 or older, those over 18 with high risk, or over 18 with high exposure from their work, can now receive a booster.

All adults who received the J&J vaccine, a single shot, more than two months ago also

Previously, only immunosuppressed people or people who were in the elderly or high-risk groups, and who had received the Pfizer vaccine, were initially eligible for a booster.

Data from emerging research reviewed by the FDA.

“Today’s actions demonstrate our commitment to public health in the proactive fight against the COVID-19 pandemic.”, highlighted the commissioner in charge of FDA, Janet Woodcock.

The statement also warned of unusual side effects associated with vaccines.

The messenger RNA vaccines, Pfizer and Moderna, have been associated with an increased risk of especially in young men.

The J&J vaccine has been linked to a rare type of and in combination with low platelet levels one to two weeks after administration. The risk is highest among women ages 18 to 49.

Follow us on twitter: